

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/22520> holds various files of this Leiden University dissertation

Author: Linnemann, Carsten

Title: Enginee ring T cell immunity by TCR gene transfer

Issue Date: 2013-11-27



ADDENDUM

| CURRICULUM VITAE

Carsten Linnemann was born on August, 7th 1981 in Soest (Germany). In 2001 he obtained his university-entrance diploma at the Conrad-von-Soest Gymnasium in Soest. After social services he started his studies on Biochemistry at University Bielefeld in 2002. After his pre-diploma in 2004, the German Academic Foundation (Studienstiftung des deutschen Volkes) supported his further studies in which he focused on immunology and gene technology. In 2006, he joined the laboratory of Ton Schumacher at the Netherlands Cancer Institute in Amsterdam for a lab rotation working on conditional MHC-class I ligand technology. He obtained his diploma (*cum laude*) in 2007, after completing a research project on the role of adenosine for the regulation of liver-induced T cell tolerance in the laboratory of Percy Knolle at the Institute for Molecular Medicine and Experimental Immunology in Bonn. Following his specific interest in immunotechnology, he returned to Amsterdam in 2008 for his PhD-research in the Schumacher lab. The results of this work are presented in this thesis. From 2009 until 2011 he was a fellow of the PhD fellowship programme of the Boehringer-Ingelheim Fonds – Foundation for Basic Research in Biomedicine.

Currently, Carsten continues his scientific work within the Schumacher laboratory with studies on kinship and antigen-specificities of intratumoral T cell subsets.

| LIST OF PUBLICATIONS

Bendle G.M.*, Linnemann C.*, Bies L., Song J.Y. and Schumacher T.N.M.

Blockade of TGF- β signaling greatly enhances the efficacy of TCR gene therapy of cancer. *J Immunol. (In press)*.

Turchaninova M.A.*, Britanova O.V.*, Bolotin D.A.*, Shugay M.*, Putintseva E.V., Staroverov D.B., Sharonov G., Shcherbo D., Zvyagin I.V., Mamedov I.Z., Linnemann C., Schumacher T.N. and Chudakov D.M.

Pairing of T-cell receptor chains via emulsion PCR.

Eur J Immunol. [Epub ahead of print] (2013).

Linnemann C., Heemskerk B.*, Kvistborg P.*, Kluin R.J.C., Bolotin D.A., Chen X., Bresser K., Nieuwland M., Schotte R., Michels S., Gomez-Eerland R., Jahn L., Hombrink P., Legrand N., Shu C.J., Mamedov I.Z., Velds A., Blank C.U., Haanen J.B.A.G., Turchaninova M.A., Kerkhoven R.M., Spits H., Hadrup S.R., Heemskerk M.H.M., Blankenstein T., Chudakov D.M., Bendle G.M.[#] and Schumacher T.N.M.[#]

High-throughput identification of antigen-specific TCRs by TCR gene capture.

Nat Med. (In press).

Schiedel A.C.*, Lacher S.K.*, Linnemann C., Knolle P.A., Müller C.E.

Antiproliferative effects of selective adenosine receptor agonists and antagonists on human lymphocytes: evidence for receptor-independent mechanisms.

Purinergic Signalling. [Epub ahead of print] (2013).

Kvistborg P.*, Shu C.J.*, Heemskerk B., Fankhauser M., Thruw C.A., Toebes M., van Rooij N., Linnemann C., van Buuren M.M., Urbanus J.H., Beltman J.B., Thor Straten P., Li Y.F., Robbins P.F., Besser M.J., Schachter J., Kenter G.G., Dudley M.E., Rosenberg S.A., Haanen J.B., Hadrup S.R. and Schumacher T.N.M.

TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. *Oncoimmunology. 4:409-418 (2012)*.

Linnemann C., Schumacher T.N.M. and Bendle G.M.

T cell receptor gene therapy: critical parameters for clinical success.

J Invest Dermatol. 9:1806-16 (2011).

Bendle G.M.*, Linnemann C.*, Hooijkaas A.I., Bies L., de Witte M.A., Jooritsma A., Pouw N., Kaiser A.K.M., Debets R., Kieback E., Uckert W., Song J.Y., Haanen J.B.A.G. and Schumacher T.N.M.

Lethal Graft-versus-Host Disease in mouse models of T Cell Receptor Gene Therapy.

Nat Med. 5: 565-70 (2010).

Linnemann C.*, Schildberg F.A.*, Schurich A.*, Diehl L., Hegenbarth S.I., Endl E., Lacher S., Müller C.E., Frey J., Simeoni L., Schraven B., Stabenow D. and Knolle P.A.

Adenosine regulates CD8 T cell priming by inhibition of membrane-proximal T cell receptor signaling.

Immunology. 128(1Suppl):e728-37 (2009).

Bakker A.H., Hoppes R.*, **Linnemann C.***, Toebes M., Rodenko B., Berkers C.R., Hadrup S.R., van Esch W.J., Heemskerk M.H., Ovaa H., and Schumacher T.N.
Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7.
Proc Natl Acad Sci U S A. 10:3825-30 (2008).

* and #: These authors contributed equally